NASDAQ:EYPT Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $3.18 +0.04 (+1.11%) As of 12:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EYPT alerts:Sign Up Key Stats Today's Range$3.08▼$3.2950-Day Range$3.15▼$14.7552-Week Range$3.05▼$19.11Volume710,239 shsAverage Volume2.12 million shsMarket Capitalization$274.58 millionP/E RatioN/ADividend YieldN/APrice Target$25.70Consensus RatingHold Company Overview EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions. EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery. The company also maintains a development pipeline centered on retinal diseases and other ophthalmic conditions. The company was formerly known as pSivida Corp. and adopted the EyePoint Pharmaceuticals name in 2018. Based in Watertown, Massachusetts, EyePoint develops and markets its therapies primarily for the U.S. ophthalmology market while pursuing additional development and commercial opportunities through collaborations and international regulatory activities.AI Generated. May Contain Errors. Read More Eyepoint Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreEYPT MarketRank™: Eyepoint Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 317th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialEyepoint Pharmaceuticals has a consensus price target of $25.70, representing about 715.9% upside from its current price of $3.15.Amount of Analyst CoverageEyepoint Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eyepoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.51) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eyepoint Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.22% of the float of Eyepoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 6.43.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently increased by 9.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.19 News SentimentEyepoint Pharmaceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat Follows5 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.13% of the stock of Eyepoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eyepoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EYPT Stock News HeadlinesHead-To-Head Analysis: Eyepoint Pharmaceuticals (NASDAQ:EYPT) versus GSK (NYSE:GSK)October 4 at 12:14 PM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTOctober 1, 2026 | prnewswire.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.October 6 at 1:00 AM | Stansberry Research (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 29, 2026 | globenewswire.comJonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)September 29, 2026 | theglobeandmail.comEyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Hold" from AnalystsSeptember 29, 2026 | americanbankingnews.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Upgraded by Wall Street ZenSeptember 27, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 24, 2026 | prnewswire.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? Eyepoint Pharmaceuticals' stock was trading at $18.27 at the beginning of the year. Since then, EYPT shares have decreased by 82.8% and is now trading at $3.15. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its earnings results on Wednesday, August, 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by $0.08. The firm earned $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative trailing twelve-month return on equity of 135.81%. When did Eyepoint Pharmaceuticals' stock split? Eyepoint Pharmaceuticals's stock reverse split on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings8/05/2026Today10/06/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EYPT's financial health is in the Red zone, according to TradeSmith. EYPT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EYPT CIK1314102 Webwww.eyepoint.bio Phone(617) 926-5000Fax617-926-5050Employees214Year Founded1987Price Target and Rating Average Price Target for Eyepoint Pharmaceuticals$25.70 High Price Target$68.00 Low Price Target$4.00 Potential Upside/Downside+703.9%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$231.96 million Net Margins-10,994.73% Pretax Margin-10,989.85% Return on Equity-135.81% Return on Assets-108.35% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.46 Sales & Book Value Annual Sales$31.37 million Price / Sales8.79 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book0.86Miscellaneous Outstanding Shares86,210,000Free Float81,789,000Market Cap$275.61 million OptionableOptionable Beta1.67 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:EYPT) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts